文献速递乳腺介入US乳腺X线MR

图像引导乳腺活检中抗血栓治疗暂停与否的出血事件比较

Bleeding Events After Image-Guided Breast Biopsies: Comparison of Patients Temporarily Discontinuing Versus Maintaining Antithrombotic Therapy During Biopsy.
PubMed 文献 · AJR Am J Roentgenol · 2023-05-10

该回顾性研究纳入5302例接受图像引导乳腺或腋窝空心针活检的患者,比较未使用抗血栓治疗、暂时停用抗血栓治疗及继续抗血栓治疗三组活检后出血事件频率。结果显示暂时停用与继续抗血栓治疗组在影像可见血肿和可触及血肿发生率上无显著差异,但继续治疗组瘀斑风险更高,无患者出现需临床干预的显著血肿。

要点

  • 继续抗血栓治疗并未显著增加影像可见或可触及血肿风险,支持活检期间继续用药的安全性。
  • 无患者发生需引流、就诊或住院的临床显著血肿,整体出血风险低。

关键影像表现/征象

  • 无患者发生需引流、就诊或住院的临床显著血肿。

临床应用与阅片要点

  • 对于抗血栓治疗患者,可考虑不中断治疗直接进行乳腺空心针活检,避免血栓事件和诊断延迟。
  • 继续抗血栓治疗者应告知瘀斑风险较高,但影像可见或可触及血肿风险与停药者无显著差异。

局限性

  • 单中心回顾性设计,可能存在选择偏倚。
  • 样本中继续抗血栓治疗组仅214例,事件数较少。
  • 抗血栓药物种类和剂量未在摘要中详细说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Antithrombic (AT) therapy is commonly temporarily discontinued before breast core needle biopsy (CNB), introducing risks of thrombotic events and diagnostic delay. OBJECTIVE. The purpose of this article was to compare the frequency of postbiopsy bleeding events among patients without AT use, patients temporarily discontinuing AT therapy, and patients maintaining AT therapy during breast CNB. METHODS. This retrospective study included 5302 patients (median age, 52 years) who underwent image-guided breast or axillary CNB between January 1, 2014, and December 31, 2019. From January 1, 2014, to December 31, 2016, patients temporarily discontinued all AT therapy for 5 days before CNB; from January 1, 2017, to December 31, 2019, patients maintained AT therapy during CNB. Immediate postbiopsy mammograms were reviewed for imaging-apparent hematoma. Patients were called 24-48 hours after biopsy and asked regarding palpable hematoma and breast bruise. The EMR was reviewed for clinically significant postbiopsy hematoma (i.e., hematoma requiring drainage, primary care or emergency department visit for persistent symptoms, or hospital admission). Bleeding events were compared among groups, including Firth bias-reduced multivariable logistic regression analysis. RESULTS. During CNB, 4665 patients were not receiving AT therapy, 423 temporarily discontinued AT therapy, and 214 maintained AT therapy. Imaging-apparent hematoma occurred in 3% of patients without AT use, 6% of patients discontinuing AT therapy, and 7% of patients maintaining AT therapy (p = .60 [discontinuing vs maintaining]). Palpable hematoma occurred in 2% of patients without AT use, 4% of patients maintaining AT therapy, and 4% of patients discontinuing AT therapy (p = .92 [discontinuing vs maintaining]). Breast bruise occurred in 2% of patients without AT use, 1% of patients discontinuing AT therapy, and 6% of patients maintaining AT therapy (p < .001 [discontinuing vs maintaining]). In multivariable analysis adjusting for age, biopsy imaging modality, needle gauge, number of biopsy samples, and pathologic result, discontinued AT therapy (using maintained AT therapy as reference) was not a significant independent predictor of imaging-apparent hematoma (p = .23) or palpable hematoma (p = .91) but independently predicted decreased risk of bruise (OR = 0.11, p < .001). No patient developed clinically significant postbiopsy hematoma. CONCLUSION. Frequencies of imaging-apparent and palpable hematoma were not significantly different between patients temporarily discontinuing versus maintaining AT therapy. CLINICAL IMPACT. The findings support the safety of continuing AT therapy during CNB. Patients who maintain AT therapy should be counseled regarding risk of bruise.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Reichman, McMahon, Dwyer, et al. Bleeding Events After Image-Guided Breast Biopsies: Comparison of Patients Temporarily Discontinuing Versus Maintaining Antithrombotic Therapy During Biopsy. AJR Am J Roentgenol. 2023. PMID: 37162038. doi:10.2214/AJR.23.29164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。